Friday, May 4, 2012

Asahi Kasei Completes Acquisition of ZOLL

 ZOLL  Asahi Kasei 

Asahi Kasei Completes Acquisition of ZOLL  

 Tokyo, Japan/ New York, NY, U.S. – April 27/26, 2012 – Asahi Kasei Corporation (TSE1: 3407, hereinafter: Asahi Kasei), Japan’s leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the successful completion of its acquisition of ZOLL Medical Corporation (hereinafter: ZOLL), a major US manufacturer of medical devices for critical care, on April 26, 2012, US Eastern time.
On March 12, 2012, Asahi Kasei announced a tender offer for shares of ZOLL, through a US subsidiary.  All procedures related to this acquisition were completed on April 26, 2012, US Eastern time, and ZOLL became a wholly owned consolidated subsidiary of Asahi Kasei.
As a result, ZOLL’s stock will cease to be traded on the NASDAQ market, and ZOLL will no longer have reporting obligations under the Securities Exchange Act of 1934.  ZOLL will continue to be managed by its current management team.

Covidien to acquire Oridion in all-cash transaction

  • Covidien announces its intent to acquire Oridion Systems Ltd. in an all-cash transaction of USD 23 per Oridion share, representing total equity value of approximately USD 346 million for Oridion on a fully diluted basis
  • Transaction has been unanimously recommended by each of Oridion’s and Covidien's Board of Directors
  • Based on an exchange rate of CHF 0.9167 to USD 1.00 on April 4, 2012 the transaction price per Oridion share is equivalent to approximately CHF 21.08 and represents a premium of 91% to the volume-weighted average share price of the last 60 trading days and a premium of 76% to the closing price on April 4, 2012
  • Covidien plans to integrate Oridion as a center of excellence in Capnography within its Medical Devices segment

Masimo Debuts 2012 Radical-7® at World Congress of Anaesthesiologists

Irvine, California – March 26, 2012 – Masimo (NASDAQ: MASI), the inventor of rainbow Pulse CO-Oximetry™, rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, debuted its 2012 Radical-7 monitor at the 15th World Congress of Anaesthesiologistsconference in Buenos Aires, Argentina, March 25-30, 2012.
Radical-7 vertical and  horizontal
Automatic rotational screen for either
horizontal or vertical display
Once again raising the technologic bar, the 2012 Radical-7 leverages Masimo's breakthrough noninvasive measurements with breakthrough functionality designed to automate the process of care and enable clinicians to instantly adapt to changing monitoring needs in individual patients and care areas.
The 2012 Radical-7's upgradeable rainbow® SET platform features noninvasive and continuous monitoring of:
  • Blood constituents that previously required invasive or complicated procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), pleth variability index (PVI®), carboxyhemoglobin (SpCO®), and methemoglobin (SpMet®)
  • Masimo SET measure-through motion and low perfusion pulse oximetry for oxygen saturation (SpO2), pulse rate, and perfusion index
  • Respiration rate through a novel acoustic sensor (RRa™) clinically shown to be as accurate if not more than capnography for respiration rate, or even through the plethysmograph waveform (RRp™), though less reliable than RRa.
Detachable, battery-operated, wireless handheld or wearable device to facilitate untethered monitoring during transport and ambulation with built-in wi-fi.
The 2012 Radical-7 is rainbow® centric, with its intuitive, gesture-control, touch screen that allows SpHb, SpOC, SpCO, SpMet, and RRa to be viewed as prominently as SpO2 and pulse rate. The 2012 Radical-7 offers exceptionally easy operation and instant adaptability to change displays and settings on the fly. With a quick touch, drag, and drop, clinicians can move any parameter to and from center and bottom of the display, never losing track of any vital signs. The instant-trend feature provides the ability to view one or two parameters at once and with a simple finger gesture, clinicians can move, expand, or collapse parameter trends for real-time analysis. Standard wireless connectivity from integrated 802.11 and Bluetooth® technology in the handheld Radical-7 keeps patients connected even while they are ambulating to enable clinician notification and automate charting and enable meaningful use of electronic health record systems.
The 2012 Radical-7 includes a variety of features designed to simplify the clinician's life. Adaptive Threshold Alarm™, helps clinicians manage nuisance alarms and reduces the time required to set patient-specific alarms by automatically adjusting the audible alarm to the patient's baseline. In Vivo Adjustment™, allows clinicians to adjust the noninvasive measurements to the specific patient and laboratory reference device they use for invasive blood testing. These capabilities received the CE Mark in 2011 and are pending FDA 510(k) clearance.
The Radical-7 offers unprecedented versatility in multiple care areas with its automatic rotational screen for either horizontal or vertical display and three-in-one capability to be used as: 1) a standalone device for bedside monitoring; 2) a detachable, battery-operated wireless device handheld or wearable device to facilitate untethered monitoring during transport and ambulation; and 3) a multiparameter monitoring interface via SatShare®, allowing hospitals to seamlessly implement rainbow® measurement capabilities in the Radical-7 display while automatically sending the Radical-7's Masimo SET pulse oximetry measurements for display on the multiparameter monitor.
Intuitive, gesture-control, touchscreen for exceptionally easy operation and instantly adaptable functionality.
The 2012 Radical-7 continues to provide respiration rate with unprecedented ease and reliability via revolutionary rainbow Acoustic Monitoring™. The Radical-7 now also includes the ability to measure respiration rate from the plethysmograph waveform (RRp™), enabling monitoring of breathing status from a standard Masimo SET pulse oximetry or rainbow® Pulse CO-Oximetry sensor in all patients in whom those sensors are indicated. The RRp measurement received the CE Mark in March 2011 and has been available on the Rad-87® monitor, but this is the first time it is available on the Radical-7 in CE Mark countries. The RRp measurement is determined by the variations in the plethysmograph waveform due to respiration, although the measurement is not possible in all patients or conditions. For patients in whom reliable and continuous respiration rate monitoring is required, Masimo's acoustic respiration rate (RRa) measurement provides accurate and patient-tolerant monitoring of breathing through an acoustic sensor placed on the neck. The Radical-7's RRa measurement also provides an important visual indication of breathing through the displayed acoustic waveform.
The 2012 Radical-7 unleashes the power of rainbow® to help empower clinicians to improve patient outcomes and reduce the cost of care in multiple ways, such as reducing blood transfusion-related costs and detecting bleeding earlier with SpHb, optimizing fluid management with PVI, and enabling reliable detection of respiratory depression with RRa.
Joe Kiani, Masimo CEO and Chairman of the Board, stated: "We are very proud to introduce the 2012 Radical-7 to the anesthesia community at the World Congress of Anaesthesiologists. In 2000, we 'wowed' the healthcare industry with the original Radical. We believe the industry will once again be 'wowed' by the new clinician-centric Radical-7 and what it can do to improve the process of care and ultimately, patient care."
The 2012 Radical-7 can be seen at the World Congress of Anaesthesiologists at Exhibit 64-65. Masimo also will be hosting a sold-out industry symposium, "Improved Patient Outcomes and Decreased Cost of Care with Masimo rainbow® Technology," on Monday, March 26. In addition, Masimo will be hosting educational seminars in Exhibit 64-65 throughout the meeting.